Ani Pharmaceuticals [ANIP] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison
Ani Pharmaceuticals
NASDAQ
Loading...
Haleon Plc - ADR
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Ani Pharmaceuticals wins in 8 metrics, Haleon Plc - ADR wins in 11 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ani Pharmaceuticals | Haleon Plc - ADR | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.63 | 19.73 | Haleon Plc - ADR |
| Price-to-Book Ratio | 4.16 | 5.03 | Ani Pharmaceuticals |
| Debt-to-Equity Ratio | 136.10 | 53.41 | Haleon Plc - ADR |
| PEG Ratio | -0.14 | 21.14 | Ani Pharmaceuticals |
| EV/EBITDA | 21.49 | 33.55 | Ani Pharmaceuticals |
| Profit Margin (TTM) | -1.37% | 13.81% | Haleon Plc - ADR |
| Operating Margin (TTM) | 7.18% | 22.21% | Haleon Plc - ADR |
| EBITDA Margin (TTM) | 7.18% | 22.21% | Haleon Plc - ADR |
| Return on Equity | -2.17% | 9.38% | Haleon Plc - ADR |
| Return on Assets (TTM) | 1.09% | 4.61% | Haleon Plc - ADR |
| Free Cash Flow (TTM) | $47.06M | $2.67B | Haleon Plc - ADR |
| Dividend Yield | N/A | 1.63% | N/A |
| 1-Year Return | 55.01% | -13.69% | Ani Pharmaceuticals |
| Price-to-Sales Ratio (TTM) | 2.70 | 3.59 | Ani Pharmaceuticals |
| Enterprise Value | $2.24B | $118.80B | Haleon Plc - ADR |
| EV/Revenue Ratio | 3.00 | 8.00 | Ani Pharmaceuticals |
| Gross Profit Margin (TTM) | 64.70% | 55.38% | Ani Pharmaceuticals |
| Revenue per Share (TTM) | $38 | $2 | Ani Pharmaceuticals |
| Earnings per Share (Diluted) | $-0.68 | $0.45 | Haleon Plc - ADR |
| Beta (Stock Volatility) | 0.63 | 0.23 | Haleon Plc - ADR |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Ani Pharmaceuticals vs Haleon Plc - ADR Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ani Pharmaceuticals | 0.57% | -3.66% | -5.56% | 37.32% | 31.26% | 61.69% |
| Haleon Plc - ADR | 0.79% | 1.47% | -9.50% | -12.68% | -14.35% | -5.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ani Pharmaceuticals | 55.01% | 177.87% | 191.23% | 110.08% | 46.47% | -21.70% |
| Haleon Plc - ADR | -13.69% | 46.96% | 20.78% | 20.78% | 20.78% | 20.78% |
News Based Sentiment: Ani Pharmaceuticals vs Haleon Plc - ADR
Ani Pharmaceuticals
News based Sentiment: POSITIVE
The launch of Prucalopride with 180-day exclusivity is a significant positive development for ANI Pharmaceuticals, offering a clear revenue opportunity. Combined with a solid financial position and a 'Buy' rating from analysts, the month's events paint a favorable picture for investors.
Haleon Plc - ADR
News sentiment data is not available for Haleon Plc - ADR at this time.
Performance & Financial Health Analysis: Ani Pharmaceuticals vs Haleon Plc - ADR
| Metric | ANIP | HLN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.99B | $41.44B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 334,370 | 9,039,612 |
| 90 Day Avg. Volume | 387,590 | 8,909,391 |
| Last Close | $89.64 | $8.95 |
| 52 Week Range | $52.50 - $99.50 | $8.71 - $11.42 |
| % from 52W High | -9.91% | -21.63% |
| All-Time High | $450.00 (May 29, 2000) | $11.42 (Jun 02, 2025) |
| % from All-Time High | -80.08% | -21.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.53% | -0.01% |
| Quarterly Earnings Growth | 0.53% | 0.33% |
| Financial Health | ||
| Profit Margin (TTM) | -0.01% | 0.14% |
| Operating Margin (TTM) | 0.07% | 0.22% |
| Return on Equity (TTM) | -0.02% | 0.09% |
| Debt to Equity (MRQ) | 136.10 | 53.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.70 | $1.77 |
| Cash per Share (MRQ) | $11.12 | $0.08 |
| Operating Cash Flow (TTM) | $139.14M | $3.35B |
| Levered Free Cash Flow (TTM) | $89.39M | $2.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.63% |
| Last 12-Month Dividend | N/A | $0.17 |
Valuation & Enterprise Metrics Analysis: Ani Pharmaceuticals vs Haleon Plc - ADR
| Metric | ANIP | HLN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.63 | 19.73 |
| Forward P/E | 16.31 | 21.14 |
| PEG Ratio | -0.14 | 21.14 |
| Price to Sales (TTM) | 2.70 | 3.59 |
| Price to Book (MRQ) | 4.16 | 5.03 |
| Market Capitalization | ||
| Market Capitalization | $1.99B | $41.44B |
| Enterprise Value | $2.24B | $118.80B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.00 | 8.00 |
| Enterprise to EBITDA | 21.49 | 33.55 |
| Risk & Other Metrics | ||
| Beta | 0.63 | 0.23 |
| Book Value per Share (MRQ) | $21.70 | $1.77 |
Financial Statements Comparison: Ani Pharmaceuticals vs Haleon Plc - ADR
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ANIP | HLN |
|---|---|---|
| Revenue/Sales | $197.12M | $3.71B |
| Cost of Goods Sold | $73.04M | $1.66B |
| Gross Profit | $124.09M | $2.06B |
| Research & Development | $10.56M | $104.91M |
| Operating Income (EBIT) | $14.10M | $470.76M |
| EBITDA | $37.19M | $486.90M |
| Pre-Tax Income | $19.99M | $387.37M |
| Income Tax | $4.31M | $88.77M |
| Net Income (Profit) | $15.68M | $298.60M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ANIP | HLN |
|---|---|---|
| Cash & Equivalents | $149.80M | $909.24M |
| Total Current Assets | $536.29M | $5.57B |
| Total Current Liabilities | $201.82M | $6.41B |
| Long-Term Debt | $611.63M | $10.28B |
| Total Shareholders Equity | $443.47M | $21.52B |
| Retained Earnings | $-85.00M | $36.67B |
| Property, Plant & Equipment | N/A | $2.51B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ANIP | HLN |
|---|---|---|
| Operating Cash Flow | $42.64M | N/A |
| Capital Expenditures | $-2.47M | N/A |
| Free Cash Flow | $15.15M | N/A |
| Debt Repayment | $-2.03M | N/A |
| Common Stock Repurchase | $-10.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ANIP | HLN |
|---|---|---|
| Shares Short | 2.05M | 15.71M |
| Short Ratio | 4.35 | 1.93 |
| Short % of Float | 0.12% | 0.00% |
| Average Daily Volume (10 Day) | 334,370 | 9,039,612 |
| Average Daily Volume (90 Day) | 387,590 | 8,909,391 |
| Shares Outstanding | 21.11M | 12.30B |
| Float Shares | 18.08M | 8.99B |
| % Held by Insiders | 0.10% | 0.00% |
| % Held by Institutions | 0.95% | 0.13% |
Dividend Analysis & Yield Comparison: Ani Pharmaceuticals vs Haleon Plc - ADR
| Metric | ANIP | HLN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.17 |
| Last 12-Month Dividend Yield | N/A | 1.63% |
| 3-Year Avg Annual Dividend | N/A | $0.11 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $0.34 |
| Ex-Dividend Date | N/A | Apr 25, 2025 |